FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498 · cited 1×
“By contrast, concurrent TP53 mutations are frequent in many other cancer types, especially intestinal-type gastric cancers harbouring FGFR2 , EGFR , ERBB2 , MET , KRAS or PIK3CA amplifications 137 , including TP53 driver alterations in 28 of 57 (49”
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864 · cited 1×
“…with lutetium-177 ( 177 Lu)–PSMA-617, which uses a small-molecule ligand for the delivery of a radionuclide to castration-resistant prostate tumours 164 suggests that small-molecule ligands, instead of monoclonal antibodies, might be better tolerated owing to their rapid clearance, which reduces…”
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050 · cited 1×
“FGFR#b and FGFR#c are splice variants derived from FGFR1 – 3 with distinct ligand-binding affinities, owing to divergence in the latter half of the third immunoglobulin-like domain 27,30 .”
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
Kamoun, A., de Reyniès, A., Allory, Y., Sjödahl, G., Robertson, A. G., Seiler, R., Hoadley, K. A., Groeneveld, C. S., Al-Ahmadie, H., Choi, W., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.09.006 · Cited by 1,359
FGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904 · cited 1×
“This complex regulates phosphate resorption in the kidney via repression of sodium phosphate cotransporters (NPT2a/c) 105 .”
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Bluemn, E. G., Coleman, I. M., Lucas, J. M., Coleman, R. T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R. F., Kaipainen, A., Corella, A. N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.003 · Cited by 744 · cited 2×
“LNCaP-APIPC cells, an AR signalling-independent LNCaP subline derived from a widely used hormone-sensitive adenocarcinoma cell line, are sensitive to the FGFR inhibitors PD173074 and zoligratinib 183 .”
Protein degraders enter the clinic — a new approach to cancer therapy
Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00736-3 · Cited by 658 · cited 2×
“Heterobifunctional protein degraders (HPDs, also known as proteolysis-targeting chimeras (PROTACs) and other classes of heterobifunctional molecule) 138–141 , chimeric antigen receptor (CAR) T cells 142–145 and bio-logics, such as monoclonal antibodies 146–149 , antibody–drug conjugates (ADCs)…”
The sequences of 150,119 genomes in the UK Biobank
Halldorsson, B. V., Eggertsson, H. P., Moore, K. H. S., Hauswedell, H., Eiriksson, O., Ulfarsson, M. O., Palsson, G., Hardarson, M. T., Oddsson, A., Jensson, B. O., et al. (2022) · Nature · doi:10.1038/s41586-022-04965-x · Cited by 448
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
Metadata
- Authors
- Katoh, M., Loriot, Y., Brandi, G., Tavolari, S., Wainberg, Z. A., & Katoh, M.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2024-02-29
- Volume
- 21
- Issue
- 4
- Pages
- 312-329
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W4392284056
- Cited by
- 195
- References
- 13
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. https://app.cochat.ai/papers/10.1038/s41571-024-00869-z
- The paper
- Katoh, M., Loriot, Y., Brandi, G., Tavolari, S., Wainberg, Z. A., & Katoh, M. (2024). FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-024-00869-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.